We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+5.31%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$999M
AUM Growth
+$357M
Cap. Flow
+$419M
Cap. Flow %
41.94%
Top 10 Hldgs %
54.5%
Holding
94
New
23
Increased
23
Reduced
18
Closed
26

Top Buys

Rank Stock Value
1
SNN icon
Smith & Nephew
SNN
+$20.4M
2
APEN
Apollo Endosurgery, Inc.
APEN
+$20M
3
KYNB
Kyntra Bio
KYNB
+$19.3M
4
NRIX icon
Nurix Therapeutics
NRIX
+$14.5M
5
ORGO icon
Organogenesis Holdings
ORGO
+$14.4M

Top Sells

Rank Stock Value
1
FLXN
Flexion Therapeutics, Inc.
FLXN
+$12.7M
2
NEO icon
NeoGenomics
NEO
+$9.19M
3
CDNA icon
CareDx
CDNA
+$8.03M
4
HOWL icon
Werewolf Therapeutics
HOWL
+$7.53M
5
CCCC icon
C4 Therapeutics
CCCC
+$7.49M

Sector Composition

Rank Sector Weight
1 Healthcare 70.82%
2 Financials 0.64%
3 Consumer Staples 0%
4 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STE icon
26
Steris
STE
$22.6B
$12.7M 1.27%
+52,100
New +$11.9M
XENE icon
27
Xenon Pharmaceuticals
XENE
$6.19B
$11.8M 1.19%
378,997
+163,300
+76% +$4.88M
CVRX icon
28
CVRx
CVRX
$147M
$11.8M 1.18%
962,165
+343,100
+55% +$4.98M
EOLS icon
29
Evolus
EOLS
$400M
$8.2M 0.82%
1,258,889
+615,955
+96% +$4.23M
XLO icon
30
Xilio Therapeutics
XLO
$59.8M
$7.64M 0.76%
+34,107
New +$8.13M
PCVX icon
31
Vaxcyte
PCVX
$7.88B
$7.01M 0.7%
294,750
-60,900
-17% -$1.42M
SIEN
32
DELISTED
Sientra, Inc.
SIEN
$6.94M 0.7%
189,188
-49,418
-21% -$2.39M
INSP icon
33
Inspire Medical Systems
INSP
$1.81B
$6.32M 0.63%
27,450
-3,500
-11% -$855K
BVS icon
34
Bioventus
BVS
$904M
$6.21M 0.62%
428,397
+333,795
+353% +$4.75M
PCRX icon
35
Pacira BioSciences
PCRX
$1.06B
$6.11M 0.61%
101,600
+35,600
+54% +$1.96M
LKFT
36
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.74B
$5.45M 0.55%
98,800
-16,500
-14% -$861K
TVRD
37
Tvardi Therapeutics
TVRD
$19M
$5.2M 0.52%
+11,867
New +$5.96M
YMAB
38
DELISTED
Y-mAbs Therapeutics
YMAB
$5.03M 0.5%
310,494
+44,794
+17% +$957K
KDNY
39
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$4.87M 0.49%
+298,700
New +$4.25M
BAX icon
40
Baxter International
BAX
$14.4B
$4.38M 0.44%
+51,000
New +$4.11M
IOBT
41
DELISTED
IO Biotech
IOBT
$4.3M 0.43%
+672,734
New +$6.5M
DXCM icon
42
DexCom
DXCM
$32.9B
$4.17M 0.42%
+31,036
New +$4.46M
DYN icon
43
Dyne Therapeutics
DYN
$4.86B
$4.03M 0.4%
338,760
+160,400
+90% +$2.25M
ABBV icon
44
AbbVie
ABBV
$432B
$3.72M 0.37%
+27,500
New +$3.25M
ARNA
45
DELISTED
Arena Pharmaceuticals Inc
ARNA
$3.72M 0.37%
40,000
-16,800
-30% -$1.11M
CUTR
46
DELISTED
Cutera, Inc.
CUTR
$3.56M 0.36%
86,180
+71,700
+495% +$2.94M
DALS
47
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
$3.43M 0.34%
350,000
– –
VSTM icon
48
Verastem
VSTM
$512M
$3.37M 0.34%
+137,042
New +$4.33M
ARYD
49
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$2.98M 0.3%
300,000
– –
ZGNX
50
DELISTED
Zogenix, Inc.
ZGNX
$2.85M 0.28%
175,152
+4,152
+2% +$60.8K
1
2
3 4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Soleus Capital Management held 94 positions worth $999M, up 56% from $642M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Soleus Capital Management deployed $419M of net new capital in Q4 2021, opening 23 new positions and adding to 23 existing holdings. Its largest new stake was Smith & Nephew: 593,200 shares worth $20.5M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 92% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Werewolf Therapeutics, an estimated $7.53M trimmed.

  • Soleus Capital Management's largest Q4 2021 buy was Smith & Nephew: 593,200 shares worth $20.5M.
  • Soleus Capital Management added most to Nurix Therapeutics in Q4 2021, an estimated $14.5M increase.
  • Soleus Capital Management's biggest Q4 2021 reduction was Werewolf Therapeutics, cutting an estimated $7.53M.
  • Soleus Capital Management fully exited Flexion Therapeutics, Inc. in Q4 2021, selling an estimated $12.7M.
  • Soleus Capital Management's ten largest holdings make up 54% of its $999M portfolio in Q4 2021.
  • Soleus Capital Management opened 23 new positions and closed 26 in Q4 2021.
  • Soleus Capital Management's portfolio value rose 56% quarter-over-quarter to $999M.

Based on Soleus Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.